左西孟旦联合沙库巴曲缬沙坦钠治疗扩张型心肌病并心力衰竭的临床疗效  

Therapeutic effect of levosimendan combined with sakubatrox valsartan sodium for dilated cardiomyopathy patients with heart failure

作　　者：杨志超 王琦[1] 曹俊达 张文强 邹家旺 YANG Zhichao;WANG Qi;CAO Junda;ZHANG Wenqiang;ZOU Jiawang(Departmengt of Cardiology,Jiujiang NO.1 People′s Hospital,Jiangxi Province,Jiujiang 332001,China)

机构地区：[1]江西省九江市第一人民医院心血管内科,332001

出　　处：《临床合理用药杂志》2024年第3期1-4,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：九江市第一人民医院青年课题(jjsdyrnyy-qnkt07);江西省卫健委科技计划项目(202211858)。

摘　　要：目的观察左西孟旦联合沙库巴曲缬沙坦钠治疗扩张型心肌病(DCM)并心力衰竭的临床疗效。方法回顾性选取2020年1月—2022年6月于九江市第一人民医院心血管内科住院的71例DCM并心力衰竭患者为研究对象,根据治疗方法分为A组23例、B组23例和C组25例。A组患者予以常规治疗,B组患者在A组基础上加用沙库巴曲缬沙坦钠片,C组患者在B组基础上联用左西孟旦注射液。3组疗程均为1个月。比较3组临床疗效,治疗前及治疗1个月后6 min步行距离、心功能指标(每搏输出量、左心室舒张末期内径、左心室射血分数)、N末端脑钠肽前体(NT-proBNP)水平。结果治疗1月后,A、B、C组治疗总有效率分别为60.87%、56.52%、92.00%,C组总有效率高于A、B组(χ2/P=6.572/0.010、8.042/0.005)。治疗1个月后,3组6 min步行距离均较治疗前延长,且C组长于A、B组,B组长于A组(P<0.05);3组每搏输出量、左心室射血分数高于治疗前,左心室舒张末期内径小于治疗前,且C组优于A、B组,B组优于A组(P<0.05);3组血清NT-proBNP水平低于治疗前,且C组低于A、B组,B组低于A组(P<0.05)。结论左西孟旦联合沙库巴曲缬沙坦钠治疗DCM并心力衰竭可增强疗效,明显降低血清NT-proBNP水平,减轻心肌损伤,极大程度地提高心功能,增强运动耐量。Objective To analyze the clinical efficacy of levosimendan combined with sakubatrox valsartan sodium for DCM patients with heart failure.Methods From January 2020 to June 2022,71 cases of DCM patients with heart failure hospitalized in the Department of Cardiology of the Jiujiang NO.1 People′s Hospital were selected as the research objects,and the patients were divided into groups A,B,C according to different treatment methods.Patients of the group A were treated with routine treatment,patients of the group B were treated with sacubatrovalsartan sodium on the basis of group A,and patients of the group C were treated with levosimendan injection on the basis of group B.All groups were treated for 1 month.Clinical efficacy,cardiac function indexes(stroke volume,left ventricular end diastolic diameter,left ventricular ejection fraction),serum NT-proBNP levels before and after 1 month of treatment were compared among the three groups.Results Total effective rate of groups A,B,C were 60.87%,56.52%,92.00%,respectively,and the total effective rate of the group C was higher than that of the groups A,B(χ2/P=6.572/0.010、8.042/0.005).After 1 month of treatment,6 min walking distance of the three groups were longer than those before treatment,and the group C was longer than that of groups A,B,and the group B was longer than that of group A(P<0.05);Stroke volume and left ventricular ejection fraction of the three groups were higher than those before treatment,and left ventricular end diastolic diameter was less than that before treatment,and those of group C were better than groups A,B,and group B were better than those of group A(P<0.05);Serum levels of NT-proBNP of the three groups was lower than those before treatment,and the group C was lower than that of groups A,B,and the group B was lower than that of group A(P<0.05).Conclusion Levosimendan combined with sakubatrox valsartan sodium can enhance clinical effect for DCM patients with heart failure,it can obviously reduce serum NT-proBNP level and myocardial injury,and

关 键 词：扩张型心肌病 心力衰竭 左西孟旦 沙库巴曲缬沙坦钠 治疗结果 

分 类 号：R542.2[医药卫生—心血管疾病] R541.6[医药卫生—内科学]